1. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

   • Jürgen C. Becker
   • Andreas Stang
   • David Schrama

   Review 30 November 2017 Pages: 341 - 351

   

2. Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model

   • Yi Zhang
   • Zuqiang Liu
   • Zhaoyang You

   Original Article 07 November 2017 Pages: 353 - 366

   

3. Prophylactic DNA vaccine targeting Foxp3⁺ regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model

   • Afshin Namdar
   • Reza Mirzaei
   • Jamshid Hadjati

   Original Article 09 November 2017 Pages: 367 - 379

   

4. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

   • David Briere
   • Niranjan Sudhakar
   • James G. Christensen

   Original Article 09 November 2017 Pages: 381 - 392

   

5. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor

   • Bai-Le Zuo
   • Bo Yan
   • Lin-Tao Jia

   Original Article 10 November 2017 Pages: 393 - 401

   

6. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

   • Johannes Breyer
   • Ralph M. Wirtz
   • Arndt Hartmann

   Original Article 17 November 2017 Pages: 403 - 412

   

7. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737

   • Theresa Noll
   • Susanne Schultze-Seemann
   • Philipp Wolf

   Original Article 29 November 2017 Pages: 413 - 422

   

8. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

   • Larisa J. Geskin
   • Oleg E. Akilov
   • Louis D. Falo Jr.

   Original Article 04 December 2017 Pages: 423 - 434

   

9. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases

   • Yun Wang
   • Hao-cheng Lin
   • Yu-hong Li

   Original Article 04 December 2017 Pages: 435 - 444

   

10. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

    • Kamiya Mehla
    • Jarrod Tremayne
    • Michael A. Hollingsworth

    Original Article 04 December 2017 Pages: 445 - 457

    

11. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

    • Koung Jin Suh
    • Se Hyun Kim
    • Jong Seok Lee

    Original Article 04 December 2017 Pages: 459 - 470

    

12. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

    • Xu-chao Zhang
    • Xu Cao
    • Yi-long Wu

    Original Article 06 December 2017 Pages: 471 - 481

    

13. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

    • Veronika Bachanova
    • Dhifaf Sarhan
    • Jeffrey S. Miller

    Original Article 07 December 2017 Pages: 483 - 494

    

14. High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

    • Yusuke Okuma
    • Tsunekazu Hishima
    • Sadamu Homma

    Original Article 14 December 2017 Pages: 495 - 505

    

15. Acknowledgements

    ACKNOWLEDGEMENT TO REVIEWERS 07 February 2018 Pages: 507 - 511